Pharmacokinetics of tolmetin with and without concomitant administration of antacid in man
dc.contributor.author | Ayres, James W. | en_US |
dc.contributor.author | Sakmar, Ermelinda | en_US |
dc.contributor.author | Lemanowicz, E. F. | en_US |
dc.contributor.author | Hallmark, Margarette R. | en_US |
dc.contributor.author | Weidler, Donald J. | en_US |
dc.contributor.author | Wagner, John G. | en_US |
dc.contributor.author | MacKichan, J. | en_US |
dc.date.accessioned | 2006-09-11T18:01:24Z | |
dc.date.available | 2006-09-11T18:01:24Z | |
dc.date.issued | 1977-11 | en_US |
dc.identifier.citation | Ayres, J. W.; Weidler, D. J.; MacKichan, J.; Sakmar, E.; Hallmark, M. R.; Lemanowicz, E. F.; Wagner, J. G.; (1977). "Pharmacokinetics of tolmetin with and without concomitant administration of antacid in man." European Journal of Clinical Pharmacology 12(6): 421-428. <http://hdl.handle.net/2027.42/46637> | en_US |
dc.identifier.issn | 1432-1041 | en_US |
dc.identifier.issn | 0031-6970 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46637 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=598416&dopt=citation | en_US |
dc.description.abstract | The purpose of this study was to determine whether a concomitant single dose of antacid or multiple doses of antacid administered prior to, and with tolmetin, alter the pharmacokinetics of tolmetin when the drug was administered as a commercially available tablet containing tolmetin sodium. The possible effects of the antacid on plasma concentrations and urinary excretion of tolmetin and its major metabolite were evaluated following administration of: (a) tolmetin sodium alone; (b) antacid four time a day for three days prior to a single dose of tolmetin sodium, with continuation of the antacid during the day tolmetin was given; and (c) co-administration of single doses of tolmetin sodium and antacid. The twenty-four subject study was of the crossover type. There were no significant differences among treatment means for: (i) peak plasma concentrations of both tolmetin and metabolite, (ii) AUC 0–8 h and AUC 0-∞ for both tolmetin and metabolite, (iii) time to peak plasma concentration for both tolmetin and metabolite, (iv) plasma concentrations of both tolmetin and the metabolite at all sampling times (except for tolmetin at 2 h), (v) renal clearance of both tolmetin and its metabolite, and (vi) the amount of metabolite excreted in the 0–24 h urine. There were small, but significant, differences among amounts of tolmetin excreted in the 0–24 h urine. Semilogarithmic plots of both tolmetin and metabolite plasma concentrations past the peak concentrations were curved over the entire 8-h observation period; although the elimination half-life of tolmetin has been reported to be about one hour, the half-life most probably exceeds 2.6 h in most subjects. The results of this study indicate a lack of a significant drug-drug interaction between the non-steroidal anti-inflammatory agent, tolmetin sodium, and a commonly used antacid, which is a mixture of magnesium and aluminium hydroxides. | en_US |
dc.format.extent | 955647 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Antacid | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Pharmacokinetics | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Tolmetin | en_US |
dc.subject.other | Bioavailability | en_US |
dc.subject.other | Oral Dose | en_US |
dc.title | Pharmacokinetics of tolmetin with and without concomitant administration of antacid in man | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | School of Pharmacy, Oregon State University, 97331, Corvallis, Oregon, USA; College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan, USA; McNeil Laboratories, Inc., 19034, Fort Washington, Pennsylvania, USA | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | McNeil Laboratories, Inc., 19034, Fort Washington, Pennsylvania, USA | en_US |
dc.contributor.affiliationother | School of Pharmacy, Oregon State University, 97331, Corvallis, Oregon, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 598416 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46637/1/228_2004_Article_BF00561061.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00561061 | en_US |
dc.identifier.source | European Journal of Clinical Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.